Health Secretary Robert F. Kennedy Jr.'s initiative to reverse the FDA's ban on 14 peptides has drawn significant scrutiny and concern from experts regarding safety and efficacy. While Kennedy champions increased accessibility amid rapid advances in peptide therapeutics, over 60% of the public remains wary of potential misuse, prompting calls for third-party validation to ensure compliance and safety. As these changes loom, the future regulation of BPC-157 and TB-500 remains uncertain, caught in a gray market amid ongoing debates about public health and access.
“iShares Russell 2000 ETF (NYSEARCA: IWM) is up 5.4% year-to-date.”
“Gorman-Rupp (NYSE: GRC) is a pump manufacturer... Full-year 2025 net sales reached a record $682.4 million.”
“Evolv Technologies (NASDAQ: EVLV) is an AI-powered security screening company that posted striking growth last quarter. Q3 2025 revenue came in at $42.9 million.”
“Wolverine World Wide (NYSE: WWW) reported Q4 2025 results... Revenue of $517.5 million narrowly beat the $512.9 million estimate.”
“Health Secretary Robert F. Kennedy Jr. let slip on Joe Rogan’s podcast last week that the FDA will soon act to make “about 14” peptides “more accessible” — a move that’s sure to please many of his Make America Healthy Again influencer constituents who promote the amino acids for a variety of issues, including injuries and genetic disorders.”
“Kennedy, an avowed “big fan” of peptides.”
“Kennedy said the FDA, during President Joe Biden’s term, “illegally” reclassified 19 peptides to a category of substances considered potentially unsafe...”
“The Centers for Medicare and Medicaid Services extended the application deadline for drugmakers to apply to an Innovation Center initiative known as the GENEROUS Model from March 31 to April 30.”
“RFK Jr.’s Plan for Easier Access to Peptides Clashes With FDA Safety Concerns inc.com”
“Health Secretary Robert F. Kennedy Jr. plans to loosen restrictions on some peptides that the FDA previously prohibited compounding pharmacies from producing.”
“Kennedy wants to unban 14 of the 19 peptides that were placed on an FDA 'do not formulate' list in 2023.”
“Yet physicians argue that many of them don't have sufficient evidence behind them to prove that they're safe and that they work.”
